SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
PBYI

Puma Biotechnology, Inc. (NASDAQ:PBYI)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$7.05-$0.07 (-0.98%)
 
Market cap
$364M
Insider Score
Health Score
Analyst consensus
Listed since
Apr 24, 2012
Market Cap$364.47M+41.6%
Revenue (ttm)$231.82M+9.4%
Net Income$23.83M-35.6%
EPS$0.46-38.3%
Shares Out51.70M
PE Ratio14.80
Forward PE29.38
Dividendn/a
Ex-Dividend Daten/a
Volume861,208
Open$7.05
Previous Close$7.12
Day's Range$6.91 - $7.22
52-Week Range$4.84 - $11.50
Beta1.21
AnalystsBuy
Price Targetn/a
Earnings DateFeb 25, 2027

About PBYI

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.

Address
10880 Wilshire Boulevard, Los Angeles, CA, 90024, US
Market Cap
364 million
Employees
179
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$2.24M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Strong
From PBYI’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.98%
5 Days
-8.80%
1 Month
-37.39%
6 Months
-0.42%
1 Year
+41.57%

$PBYI stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of PBYI by members of U.S. Congress

Donna ShalalaHouseSale$1.00K – $15.00KMay 15, 2019
Donna ShalalaHousePurchase$1.00K – $15.00KJan 23, 2019

Recently reported changes in PBYI holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by PBYI's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

PBYI Estimated quarterly lobbying spending

Source: U.S. Senate LDA

PBYI Revenue by Segment

$15.66MTotal
Commercialization$9.79M62.53%
Stock-based compensation$5.87M37.47%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New PBYI patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to PBYI from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in PBYI

AVUVAvantis U.S. Small Cap Value ETF$18.37M
VTIVanguard Morningstar Total Stock Market ETF$11.05M
IWMiShares Russell 2000 ETF$8.44M
VXFVanguard Extended Market ETF$4.76M
DFATDimensional - US Targeted Value ETF$2.93M
VTWOVanguard Russell 2000 ETF$2.72M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from PBYI’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
56
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
18
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 17
0255075100Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 26.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 17Sep 25Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

FDMFirst Trust Dow Jones Select MicroCap Index Fund0.50%
BRSVEA Series Trust - EA Bridgeway Select Small-Cap Value ETF0.45%
AESLHarbor AlphaEdge Small Cap Value ETF0.42%
ROSCHartford Multifactor Small Cap ETF0.41%
LITLSimplify Piper Sandler US Small-Cap PLUS Income ETF0.41%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.37%
SQLVRoyce Quant Small-Cap Quality Value ETF0.27%
AESGHarbor AlphaEdge Small Cap Growth ETF0.26%
AESBHarbor AlphaEdge Small Cap Core ETF0.23%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.21%
PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF0.18%
VMO.TOVanguard Global Momentum Factor ETF0.09%

Weight is the stock’s share of each fund’s holdings.